===
EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous
BRAIN Biotech AG takes next step to optimize group structure
2024-04-16 / 11:20 CET/CEST
The issuer is solely responsible for the content of this announcement.
BRAIN Biotech AG takes next step to optimize group structure
BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and
simplify the Group structure.
Zwingenberg, Germany, 16 April 2024 - The Management Board of BRAIN Biotech AG, with the approval of the Supervisory
Board, has resolved to merge AnalytiCon Discovery GmbH with BRAIN Biotech AG. AnalytiCon Discovery GmbH, based in
Potsdam, Germany, is already a fully owned subsidiary of the BRAIN Biotech Group.
This legal reorganization will further optimize and simplify the structure of the BRAIN Biotech Group. The operational
business of both units remains unaffected and will continue unchanged at the respective locations.
Michael Schneiders, CFO of BRAIN Biotech AG, comments on the merger: "Last year we have merged our product business
under the umbrella of Biocatalysts. We are now taking the next logical step by legally combining our scientific
services in the BioScience business segment under the umbrella of the BRAIN Biotech AG. This will not result in any
noticeable changes for our employees at both locations or for our business partners."
Further documents on the resolved merger of BRAIN Biotech AG with AnalytiCon Discovery GmbH can be viewed on the
company's website at https://www.brain-biotech.com/merger-information.
+++
About BRAIN Biotech
BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins,
microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial
processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are
divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other
proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in
continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on
enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment
conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly
promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform,
which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of
specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates
for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker
symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330
people and generated revenues of EUR 55.3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

About AnalytiCon Discovery
AnalytiCon Discovery GmbH is a research and development company with many years of expertise in natural product
chemistry. The Potsdam-based company specializes in small molecule compounds and offers customers from the
pharmaceutical, cosmetics, food and agricultural sectors the development of substance libraries, the identification of
active ingredients and their synthetic optimization as well as the production of active ingredients on a commercial
scale. AnalytiCon has been part of the BRAIN Biotech Group since 2013. Further information: www.ac-discovery.com

Contact Media BRAIN Biotech
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations BRAIN Biotech
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and
assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as
uncertainties that could cause actual results, performance or events to differ materially from those expressed or
implied in such statements. Numerous factors exist that could influence the future performance of and future
developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in
the general economic and competitive environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and
regulations, as well as other factors.
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

2024-04-16 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      BRAIN Biotech AG 

Darmstädter Straße 34-36
64673 Zwingenberg
Germany

Phone:        +49 (0) 62 51 / 9331-0 
Fax:          +49 (0) 62 51 / 9331-11 
E-mail:       ir@brain-biotech.com 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1881585

End of News EQS News Service
===
1881585 2024-04-16 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1881585&application_name=news

END) Dow Jones Newswires

April 16, 2024 05:20 ET (09:20 GMT)